Benetuzumab and the Progression-Free Survival of Patients on the Drug

This is essentially a 6-year median follow-up. We're seeing really good progression-free survival and comparing very historically well, not more favorably to what we saw with I-brutinib. But even though these drugs are more selective, we still have to deal with BTK inhibitor class effects. This data set is starting to help us understand which patients that we should maybe think about adding anti-CD20 therapy to Obenetuzumab. The most impactful thing from this look at the Dell 17P and carry-type patients, so far right here, you can actually see that they do not benefit from the second-generation anti- CD20 addition.